Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Completed
Northwestern University
1995-09-01
OBJECTIVES:
I. Determine the relationship between genotype variations and clinical phenotype in patients
with congenital nephrogenic diabetes insipidus.
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Completed
National Center for Research Resources (NCRR)
1995-09-01
OBJECTIVES:
I. Determine the relationship between genotype variations and clinical phenotype in patients
with congenital nephrogenic diabetes insipidus.
Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease
Unknown status
West Virginia University Healthcare
Phase 2/Phase 3
2012-10-01
Bronchopulmonary dysplasia (BPD), also known as chronic lung disease (CLD), is a major
complication of premature birth and is associated with a significant increased risk of
complications including death. Diuretics have been used for decades in babies with BPD and
are considered a standard of care. Patients receive electrolyte supplementation to replace
the electrolytes removed by the diuretics. Spironolactone is not as good as other diuretics
at removing extra fluid, but it is different from chlorothiazide and furosemide because
instead of removing potassium, it actually can increase potassium levels in our body.
Spironolactone is used with chlorothiazide to try to minimize the potassium lost; therefore,
reduce the electrolyte supplementation needed. However, studies have suggested that preterm
babies aren´t developed enough to appropriately respond to spironolactone. Also, one study
has shown that adding spironolactone to chlorothiazide in patients with BPD has no effect on
whether or not patients receive electrolyte supplementation. This study will examine whether
there is a difference in the amount of electrolyte supplementation between patients receiving
chlorothiazide only or chlorothiazide plus spironolactone. the investigators hypothesize
there will be no difference in the amount of electrolyte supplementation between the two
groups.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
